AYTU BIOPHARMA, INC Payment for Contingent Consideration Liability, Investing Activities
AYTU BIOPHARMA, INC (AYTU) reported Payment for Contingent Consideration Liability, Investing Activities of $0 for the 6-month period ending 2023-12-31, per its 10-Q filed 2024-02-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities · last filed 2024-02-14
- AYTU BIOPHARMA, INC payment for contingent consideration liability, investing activities for the quarter ending 2022-06-30 was $40.00K.
- AYTU BIOPHARMA, INC payment for contingent consideration liability, investing activities for the quarter ending 2022-03-31 was $29.00K, a 95.47% decline year-over-year.
- AYTU BIOPHARMA, INC payment for contingent consideration liability, investing activities for the quarter ending 2021-12-31 was $3.06M, a 12645.83% increase year-over-year.
- AYTU BIOPHARMA, INC payment for contingent consideration liability, investing activities for the quarter ending 2021-09-30 was $50.00K, a 163.16% increase year-over-year.
- AYTU BIOPHARMA, INC payment for contingent consideration liability, investing activities for fiscal 2023 was $5.00K, a 99.84% decline from fiscal 2022.
- AYTU BIOPHARMA, INC payment for contingent consideration liability, investing activities for fiscal 2022 was $3.18M, a 365.30% increase from fiscal 2021.
- AYTU BIOPHARMA, INC payment for contingent consideration liability, investing activities for fiscal 2021 was $683.00K, a 236.45% increase from fiscal 2020.
- AYTU BIOPHARMA, INC payment for contingent consideration liability, investing activities for fiscal 2020 was $203.00K, a 59.80% decline from fiscal 2019.
| Period end | Payment for Contingent Consideration Liability, Investing Activities 3 month | Payment for Contingent Consideration Liability, Investing Activities 3 month as first filed | Payment for Contingent Consideration Liability, Investing Activities 6 month | Payment for Contingent Consideration Liability, Investing Activities 6 month as first filed | Payment for Contingent Consideration Liability, Investing Activities 9 month | Payment for Contingent Consideration Liability, Investing Activities 9 month as first filed | Payment for Contingent Consideration Liability, Investing Activities 12 month | Payment for Contingent Consideration Liability, Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 10-Q · filed 2024-02-14 | |||||||
| 2023-06-30 | $5.00K 10-K · filed 2023-10-12 | |||||||
| 2022-12-31 | $5.00K 10-Q · filed 2024-02-14 | |||||||
| 2022-06-30 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $69.00K derived: sum of 2 quarters · filed 2023-10-12 | $3.13M derived: sum of 3 quarters · filed 2023-10-12 | $3.18M 10-K · filed 2023-10-12 | ||||
| 2022-03-31 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | $3.09M derived: sum of 2 quarters · filed 2023-05-11 | $3.14M 10-Q · filed 2023-05-11 | $3.14M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $3.06M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-02-21 | $3.11M 10-Q · filed 2023-02-21 | $3.11M derived: sum of 3 quarters · filed 2023-02-21 | $3.75M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-09-30 | $50.00K 10-Q/A · filed 2023-02-21 | $50.00K derived: sum of 2 quarters · filed 2023-02-21 | $690.00K derived: sum of 3 quarters · filed 2023-02-21 | $714.00K derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $640.00K derived: sum of 2 quarters · filed 2022-09-27 | $664.00K derived: sum of 3 quarters · filed 2022-09-27 | $683.00K 10-K · filed 2022-09-27 | ||||
| 2021-03-31 | $640.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | $664.00K derived: sum of 2 quarters · filed 2022-05-16 | $683.00K 10-Q · filed 2022-05-16 | $683.24K 10-Q · filed 2021-05-17 | $734.35K derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $43.00K 10-Q · filed 2022-02-14 | $42.76K 10-Q · filed 2021-02-11 | $94.35K derived: sum of 3 quarters · filed 2022-02-14 | $141.37K derived: sum of 4 quarters · filed 2022-02-14 | |||
| 2020-09-30 | $19.00K 10-Q · filed 2021-11-15 | $19.14K 10-Q · filed 2020-11-12 | $70.35K derived: sum of 2 quarters · filed 2021-11-15 | $117.36K derived: sum of 3 quarters · filed 2021-11-15 | $179.90K derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $51.35K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $98.36K derived: sum of 2 quarters · filed 2021-09-28 | $160.90K derived: sum of 3 quarters · filed 2021-09-28 | $203.00K 10-K · filed 2021-09-28 | $202.69K 10-K · filed 2020-10-06 | |||
| 2020-03-31 | $47.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-17 | $109.55K derived: sum of 2 quarters · filed 2021-05-17 | $151.65K 10-Q · filed 2021-05-17 | $247.76K derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $62.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | $104.64K 10-Q · filed 2021-02-11 | $200.74K derived: sum of 3 quarters · filed 2021-02-11 | $559.44K derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-09-30 | $42.10K 10-Q · filed 2020-11-12 | $138.21K derived: sum of 2 quarters · filed 2020-11-12 | $496.91K derived: sum of 3 quarters · filed 2020-11-12 | $547.13K derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $96.11K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $454.80K derived: sum of 2 quarters · filed 2020-10-06 | $505.02K derived: sum of 3 quarters · filed 2020-10-06 | $505.02K 10-K · filed 2020-10-06 | ||||
| 2019-03-31 | $358.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-15 | $408.92K derived: sum of 2 quarters · filed 2020-05-15 | $408.92K 10-Q · filed 2020-05-15 | $408.92K derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $50.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-14 | $50.22K 10-Q · filed 2020-02-14 | $50.22K derived: sum of 3 quarters · filed 2020-02-14 | $57.61K derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | $7.38K derived: sum of 3 quarters · filed 2019-11-14 | |||||
| 2018-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $7.38K derived: sum of 2 quarters · filed 2019-09-26 | $7.38K 10-K · filed 2019-09-26 | |||||
| 2018-03-31 | $7.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-14 | $7.38K 10-Q · filed 2019-05-14 | ||||||
| 2017-12-31 | $0.00 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |